Filing Flows › Orchestra BioMed Holdings (OBIO) › Q1 2026
Orchestra BioMed Holdings (OBIO) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 12, 2026
Orchestra BioMed Holdings (OBIO) reported revenue of $110K for the first quarter 2026 (Q1 2026), -87% from a year earlier and -100% from the quarter before.
Orchestra BioMed Holdings, Q1 2026: revenue $110K (-87% year over year), net loss $20.7M, operating cash flow −$22.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $110K | -100% | -87% |
| Operating profit | −$22.1M | -427% | — |
| Net earnings | −$20.7M | -431% | — |
| Operating cash flow | −$22.2M | — | — |
What changed
Revenue was $110K in Q1 2026, down 87% year over year and down 100% from the previous quarter.
Operating costs exceeded revenue by $22.1M, an operating margin of -20069.1%. Total costs grew 12% against a revenue fall of 87%. The fastest-growing cost line was Research & development (+17%). The quarter ended with a net loss of $20.7M, after a profit of $6.2M the previous quarter.
Operating cash flow was −$22.2M. Non-cash charges added back $90K of depreciation and amortization and $2.9M of share-based compensation. Working capital and other items used $4.4M. Capital expenditures of $184K exceeded it, leaving free cash flow of −$22.4M.
Questions
What was Orchestra BioMed Holdings' revenue in the first quarter 2026?
Orchestra BioMed Holdings (OBIO) reported revenue of $110K for the first quarter 2026 (Q1 2026), -87% from a year earlier and -100% from the quarter before.